Page 14 - Area Under News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexaria Provides Progress Report on Six R&D Programs ACCESSWIRE 09 Jun 2021, 21:05 GMT+10 All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, provides this progress report on several studies within ...

27 May 2021 Plasma phospho-tau 181 and p-tau 217 can distinguish people with Alzheimer’s disease from controls most, but not all, of the time. To increase diagnostic accuracy, researchers are creating algorithms combining p-tau with other fluid biomarker and diagnostic data. In the May 24 Nature Medicine, researchers led by Oskar Hansson and Sebastian Palmqvist, both at Lund University, Sweden, reported just such an algorithm to predict AD. They report that among people with a subjective memory complaint, plasma p-tau, APOE genotype, executive function, and memory scores together predicted ...

Lexaria Bioscience Corp.: Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH 2.0" cannabidiol ("CBD") formulations in its second 2021 applied research and development study program, HYPER-A21-2. "One of ...

Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever ACCESSWIRE New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new 'DehydraTECH ™ 2.0' cannabidiol ('CBD') formulations in its second 2021 applied res...

Lexaria Bioscience Corp.: Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study HYPER-A21-1 included three new "DehydraTECH 2.0" formulation variations designed to enable cannabidiol ("CBD") delivery perform...